NIH funded study to evaluate remdesivir for COVID-19 in pregnancy
On Feb. 17, 2021, the NIH annunced funding of a study to evaluate the effects of remdesivir in…
On Feb. 17, 2021, the NIH annunced funding of a study to evaluate the effects of remdesivir in…
On Feb. 17, 2021, TGen, an affiliate of City of Hope announced that it had found a way…
On Feb. 17, 2021, LabCorp announced the availability of a new laboratory-based antigen test that will help doctors…
On Feb. 16, 2021, XPhyto and 3a-diagnostics announced that all actions and procedures required for its European regulatory…
On Feb. 16, 2021, AIM ImmunoTech announced that it had received approval from the required Ethics Committee in…
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
On Feb. 16, 2021, Meridian Bioscience provided an update on its application for Emergency Use Authorization (EUA) with…
On Feb. 15, 2021, the WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving…
On Feb. 13, 2021, the University of Oxford, together with three partner sites in London, Southampton and Bristol,…
On Feb. 12, 2021, the NIH announced that enrollment had begun to test additional investigational drugs in the…
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…